Aptahem AB Logo

Aptahem AB

Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.

APTA | SPGR

Overview

Corporate Details

ISIN(s):
SE0022447173 (+2 more)
LEI:
549300IVD1BY4CJMSO40
Country:
Sweden
Address:
Norra Vallgatan 58, 211 22 Malmö
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aptahem AB is a clinical-stage biotechnology company that develops RNA-based pharmaceuticals, known as aptamers, for the treatment of acute, life-threatening conditions involving a combination of coagulation, inflammation, and tissue damage. The company's lead candidate, Apta-1, is in clinical development with a primary indication for sepsis, a condition with a significant unmet medical need and high mortality. Apta-1 features a unique multi-mechanistic profile to address the complex pathology of sepsis. Aptahem's technology leverages synthetically produced aptamers, which offer a highly specific and low-immunogenicity alternative to traditional antibodies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aptahem AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aptahem AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aptahem AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SYNLOGIC, INC. Logo
Uses synthetic biology to engineer oral living medicines for rare metabolic disorders.
United States of America SYBX
Synthaverse S.A. Logo
Develops and sells oncology, hematology, and immunology drugs and vaccines globally.
Poland BML
TAIKO PHARMACEUTICAL CO., LTD. Logo
Manufactures OTC gastrointestinal medicine and leading infection control products.
Japan 4574
TAKARA BIO INC. Logo
Provides life science research tools, gene therapies, and CDMO services for improving human health.
Japan 4974
TAKEDA PHARMACEUTICAL CO LTD Logo
R&D-driven biopharma developing treatments for oncology, rare diseases, neuroscience, and GI.
United States of America TAK
Takeda Pharmaceutical Company Limited Logo
R&D-driven biopharma creating medicines for Oncology, Rare Diseases, GI, and Neuroscience.
Japan 4502
TALPHERA, INC. Logo
Develops therapies for acute pain and anticoagulants for medically supervised settings.
United States of America TLPH
Tango Therapeutics, Inc. Logo
Developing precision oncology therapies for genetically-defined patients via synthetic lethality.
United States of America TNGX
Tarsus Pharmaceuticals, Inc. Logo
Develops novel therapies for eye care, including the first FDA-approved Demodex blepharitis drug.
United States of America TARS
TAUNS Laboratories, Inc. Logo
Develops and sells in vitro diagnostics and research reagents, like antigen tests, globally.
Japan 197A

Talk to a Data Expert

Have a question? We'll get back to you promptly.